[Sep 30, 2025] Updates Up to 365 days On Valid ACRP-CP Braindumps
Best QualityACRP-CP Exam Questions ACRP Test To Gain Brilliante Result
NEW QUESTION # 43
The site submitted all start-up documents for a study to the sponsor and the IRB/IEC. The site also has subjects identified for screening. What should happen FIRST?
- A. Ship/receive IP
- B. Obtain IRB/IEC approval
- C. Schedule a site initiation visit
- D. Verify subject eligibility
Answer: B
Explanation:
Before proceeding with any trial-related activities, including subject screening, the site must first obtain IRB
/IEC approval. This approval ensures that the study has been reviewed for ethical considerations, risk assessment, and adherence to regulatory requirements. Without IRB/IEC approval, initiating the study would violate ethical guidelines and regulatory standards.
GCP guidelines mandate that no clinical trial procedures, including screening, commence without prior IRB
/IEC approval.
"IRB/IEC approval must be obtained before initiating any study-related activities, including screening and subject recruitment." Objectives:
* Ensure ethical compliance before study initiation.
* Protect participant rights and safety.
NEW QUESTION # 44
A double-blind randomized Phase III trial seeks to recruit 500 subjects in 2 years. At the end of the first year,
150 subjects have been enrolled. Monitoring reports from the first year note 50% of subjects screened were screen failures due to exclusionary lab values. What action should the sponsor take?
- A. Evaluate the screen failures to determine if the protocol needs revision.
- B. Re-train investigators on recruitment obligations.
- C. Reduce the target sample size based on feedback from the sites.
- D. Allocate additional monitoring resources to the trial.
Answer: A
Explanation:
The high rate of screen failures indicates that the inclusion/exclusion criteria may be too stringent or not appropriately defined. The sponsor should evaluate the reasons for these failures and determine whether the protocol needs adjustment. Revising the criteria may increase recruitment efficiency without compromising the scientific validity of the study.
GCP guidelines advise reviewing and possibly revising protocols when screen failure rates are significantly high to ensure feasible recruitment.
"If a high number of screen failures occurs, the sponsor should evaluate the inclusion/exclusion criteria and consider protocol revisions." Objectives:
* Improve recruitment efficiency.
* Adapt protocol criteria to real-world conditions.
NEW QUESTION # 45
While consenting a potential subject, a coordinator discovered the subject could not read. Under what conditions can this potential subject be enrolled?
- A. There are no circumstances under which this person can be enrolled.
- B. Locate a translator and have them work with the person.
- C. Get an impartial witness involved in consenting this person.
- D. Have the Principal Investigator consent the person.
Answer: C
Explanation:
When a participant cannot read, an impartial witness must be present during the consent process. The witness ensures that the information is accurately presented and that the subject's consent is truly informed. The witness must sign the consent form to attest that the subject understands the information.
GCP guidelines require the use of an impartial witness during the informed consent process for individuals who are illiterate or visually impaired.
"Informed consent must involve an impartial witness when the subject cannot read, ensuring the consent process is conducted ethically." Objectives:
* Maintain ethical standards during consent.
* Protect the rights of participants with literacy challenges.
NEW QUESTION # 46
While reviewing a new protocol, a PI realizes a specialized laboratory test is required that the local hospital does not perform. The PI locates a laboratory that performs the specialized test and retains their services.
Responsibility for ensuring the laboratory retained is qualified for this trial-related task lies with the:
- A. Sponsor
- B. PI
- C. CRC
- D. CRO
Answer: B
Explanation:
The Principal Investigator (PI) is responsible for ensuring that any laboratory used for trial-related testing is appropriately qualified and certified. This includes verifying the laboratory's accreditation, quality control procedures, and ability to perform the required tests accurately. The PI must document the qualification process to ensure compliance with GCP and protocol requirements.
GCP guidelines state that the investigator is responsible for selecting and verifying the qualification of laboratories used in the study.
"The PI must ensure that any laboratory involved in the trial is properly qualified and capable of performing the specified tests according to protocol requirements." Objectives:
* Maintain quality control in laboratory testing.
* Ensure the accuracy and reliability of test results.
NEW QUESTION # 47
Who is responsible for defining, establishing, and allocating all trial-related duties and functions prior to initiating a trial?
- A. Sponsor
- B. Investigator
- C. IRB/IEC
- D. CRO
Answer: A
Explanation:
The sponsor is responsible for defining, establishing, and allocating all trial-related duties and functions before the trial begins. This includes outlining roles and responsibilities in collaboration with investigators, CROs, and other stakeholders. Proper delegation ensures the trial is conducted according to protocol and regulatory requirements.
This answer is verified based on GCP guidelines, which clearly state that sponsors are responsible for the organization and management of trial-related tasks.
"The sponsor is responsible for allocating duties and functions related to the conduct of the trial, ensuring compliance with regulatory and ethical standards." Objectives:
* Clarify the sponsor's role in clinical trial management
* Define responsibilities in trial planning
NEW QUESTION # 48
The PI should ensure that source data is:
- A. On worksheets that are provided by the sponsor.
- B. Kept on site for a minimum of 2 years.
- C. Accurately reflected in the eCRFs.
- D. Printed directly from the EMR.
Answer: C
Explanation:
The PI is responsible for ensuring that the source data is accurately recorded in the electronic Case Report Forms (eCRFs). This accurate transposition of data is critical to maintaining data integrity and ensuring that the data collected at the site is consistent with the reported clinical outcomes.
GCP guidelines specify that source data should be accurate, legible, and directly reflected in the CRFs to maintain consistency and reliability.
"The PI must ensure that the source data are accurately and completely recorded in the eCRFs to maintain data integrity." Objectives:
* Ensure accurate data transposition from source to CRF.
* Maintain high standards of data quality and reliability.
NEW QUESTION # 49
The investigator/institution should permit:
- A. Monitoring and inspection by the appropriate regulatory authority(ies), and auditing by the sponsor.
- B. Monitoring and inspection by the sponsor, and auditing by the appropriate regulatory authority(ies).
- C. Monitoring and auditing by the sponsor, and inspection by the appropriate regulatory authority(ies).
- D. Monitoring and auditing by the appropriate regulatory authority(ies), and inspection by the sponsor.
Answer: A
Explanation:
The investigator and institution must allow both monitoring and inspection by the appropriate regulatory authorities and auditing by the sponsor. This dual oversight ensures that the trial complies with regulatory standards and sponsor requirements, thereby maintaining the integrity and validity of the data.
GCP guidelines specify that regulatory authorities have the right to inspect, while sponsors typically conduct audits to verify compliance and data quality.
"The institution should permit monitoring and inspection by regulatory authorities and auditing by the sponsor to ensure compliance with GCP and protocol adherence." Objectives:
* Facilitate monitoring and inspection for compliance.
* Ensure trial data integrity and quality assurance.
NEW QUESTION # 50
Which of the following activities is the MOST efficient way of overseeing a CRO's management during a clinical trial?
- A. Risk-based audits of CRO activities as delegated
- B. Central monitoring of data fields by sponsor
- C. Co-monitoring of CRO site visits
- D. Pre-qualification assessment of CRO
Answer: A
Explanation:
Risk-based audits of CRO activities as delegated are considered the most efficient way of overseeing a CRO's management. This approach focuses on evaluating the critical risks that might impact data integrity and participant safety. It allows sponsors to allocate resources to areas with the highest potential for error or deviation, rather than performing exhaustive monitoring of all activities.
The answer is verified as per guidelines on risk-based monitoring strategies, emphasizing targeted and efficient oversight of CRO functions.
"Risk-based monitoring emphasizes focusing on critical study parameters and the risks that have the potential to affect data quality and subject safety." Objectives:
* Efficient management of outsourced clinical trial tasks.
* Ensuring data integrity through targeted audits.
NEW QUESTION # 51
A protocol amendment is needed to collect additional data from a participant's medical record. When can the research team begin collecting the additional data?
- A. After the protocol amendment is approved by the IRB/IEC
- B. When the need for the additional data is discovered
- C. As soon as the protocol amendment is submitted to the IRB/IEC
- D. After the original planned data collection is completed
Answer: A
Explanation:
The research team must wait until the protocol amendment is reviewed and approved by the IRB/IEC before collecting any additional data. This ensures that any changes to the data collection process have undergone ethical review and comply with regulatory requirements. Collecting data without IRB/IEC approval would be a violation of Good Clinical Practice (GCP).
GCP guidelines clearly state that any changes to the protocol, including additional data collection, must be approved by the IRB/IEC before implementation.
"Any amendment that affects participant data collection must receive IRB/IEC approval before the change is implemented." Objectives:
* Maintain compliance with ethical standards.
* Protect participants' rights and data integrity.
NEW QUESTION # 52
The sponsor must report a serious unexpected AE to the regulatory authorities within a maximum of:
- A. 30 calendar days
- B. 8 calendar days
- C. 15 calendar days
- D. 7 calendar days
Answer: C
Explanation:
The sponsor is required to report serious unexpected adverse events (SAEs) to the regulatory authorities within 15 calendar days from the date of awareness. This reporting period is mandated to ensure that any new safety information that may affect the risk/benefit profile of the investigational product (IP) is promptly communicated, thereby protecting participant safety.
GCP guidelines specify that serious, unexpected, and related AEs must be reported to regulatory authorities within 15 days of being known to the sponsor.
"Serious unexpected adverse reactions that may affect the safety profile of the IP must be reported within 15 calendar days to the regulatory authorities." Objectives:
* Ensure timely reporting of safety information.
* Protect the safety of trial participants.
NEW QUESTION # 53
Who determines the age of assent for pediatric studies?
- A. Sponsor
- B. Parent
- C. IRB/IEC
- D. PI
Answer: C
Explanation:
The IRB/IEC determines the age at which a child is considered capable of providing assent for participation in a clinical trial. This decision is based on local regulations, cultural considerations, and the child's ability to understand the trial's risks and benefits. The age of assent may vary between jurisdictions and is subject to ethical considerations specific to pediatric research.
GCP guidelines emphasize that the IRB/IEC is responsible for setting the criteria for obtaining assent from minors based on ethical and regulatory frameworks.
"The IRB/IEC is responsible for determining the age and circumstances under which pediatric assent is required, considering the child's comprehension level." Objectives:
* Ensure appropriate ethical practices in pediatric research.
* Align with local regulatory requirements for assent.
NEW QUESTION # 54
Who takes responsibility for initiating a clinical trial?
- A. Sponsor
- B. Investigator
- C. IRB/IEC
- D. CRO
Answer: A
Explanation:
The sponsor is responsible for initiating a clinical trial. This involves developing the protocol, securing funding, selecting study sites, and obtaining regulatory approvals. The sponsor also oversees the conduct of the trial to ensure compliance with GCP and regulatory requirements.
According to GCP guidelines, the sponsor is the entity that initiates, manages, and finances the clinical investigation.
"The sponsor is responsible for initiating, managing, and financing the clinical trial, including protocol development and site selection." Objectives:
* Understand the sponsor's role in trial initiation.
* Ensure compliance from the outset of the study.
NEW QUESTION # 55
One key attribute for good study documentation is that the data are contemporaneous, which refers to the practice of:
- A. Comparing source document data to other data recorded in the same study time period.
- B. Allowing real-time access for data review in the eCRF.
- C. Recording the date and time each data element is entered onto the source document.
- D. Recording data on source documents at the time the data are collected during the conduct of the study.
Answer: D
Explanation:
Contemporaneous data means that data entries are made at the time of the event or as soon as possible after the event occurs. This practice ensures that the recorded data accurately reflect the participant's condition and study procedures, minimizing recall bias and errors. Maintaining contemporaneous records is a fundamental requirement for ensuring the accuracy and reliability of clinical trial data.
GCP guidelines specify that data should be recorded as close to the time of the event as possible to ensure accuracy and reliability.
"Data must be contemporaneously recorded, meaning they are documented at the time of the occurrence to accurately reflect the study conduct." Objectives:
* Ensure accurate and real-time data capture.
* Maintain data integrity by minimizing recall bias.
NEW QUESTION # 56
Who is responsible for outlining written procedures in a study to assure that changes or corrections in CRFs are documented, are necessary, and are endorsed by the investigator?
- A. Sponsor
- B. Data Manager
- C. CRO
- D. CRA
Answer: A
Explanation:
The sponsor is responsible for establishing written procedures to ensure that all changes or corrections in Case Report Forms (CRFs) are properly documented and justified. These procedures must include who is authorized to make changes, how corrections are documented, and how they are endorsed by the investigator.
This practice ensures data accuracy and traceability.
GCP guidelines indicate that sponsors must establish and maintain procedures for data handling and documentation to ensure accuracy and reliability.
"The sponsor should develop written procedures to ensure that CRF changes are justified, documented, and endorsed by the investigator." Objectives:
* Maintain data accuracy and consistency.
* Ensure transparent documentation practices.
NEW QUESTION # 57
The PI may assign responsibility for IP accountability to the pharmacist provided they are:
- A. Licensed to practice medicine.
- B. Under the supervision of the PI.
- C. Approved by the IRB/IEC.
- D. An employee of the institution.
Answer: B
Explanation:
The Principal Investigator (PI) can delegate the responsibility for investigational product (IP) accountability to a pharmacist as long as the pharmacist operates under the PI's supervision. This ensures that the pharmacist's actions remain compliant with the protocol and regulatory requirements.
According to GCP guidelines, the PI retains overall responsibility for IP management, even when tasks are delegated to other qualified staff members.
"The investigator may delegate IP management responsibilities to a pharmacist, provided the pharmacist works under the PI's direct supervision." Objectives:
* Maintain accountability for investigational products.
* Ensure proper delegation of IP responsibilities.
NEW QUESTION # 58
In preparation for an upcoming site audit, whose responsibility is it to ensure study-related functions were conducted by qualified personnel?
- A. Sponsor
- B. Investigator
- C. CRC
- D. CRA
Answer: B
Explanation:
The Principal Investigator (PI) holds ultimate responsibility for ensuring that all study-related functions are conducted by qualified and trained personnel. The PI must verify that staff have the necessary qualifications and training to perform their assigned tasks as outlined in the protocol. This responsibility is crucial for maintaining compliance with GCP and ensuring data integrity.
According to GCP guidelines, the PI must ensure that all staff assisting with the trial are adequately trained and qualified for their roles.
"The investigator is responsible for ensuring that all persons assisting with the trial are qualified by education, training, and experience to perform their respective tasks." Objectives:
* Maintain compliance with GCP requirements.
* Ensure qualified personnel conduct study tasks.
NEW QUESTION # 59
A deferred consent can take place in which of the following situations?
- A. Only when the PI approves such a consent process immediately prior to patient enrollment, regardless of the situation being classed as emergency.
- B. Only when the PI approves such a consent process, regardless of the emergency situation described in the protocol.
- C. In an emergency situation only, when this process is described in the protocol and has received permission from the ethics committee.
- D. In an emergency situation only, even when this process is not described in the protocol, but the sponsor approves the consent process.
Answer: C
Explanation:
Deferred consent is permissible in emergency situations where immediate intervention is necessary and obtaining prior consent is not feasible. However, this practice must be explicitly described in the protocol and approved by the ethics committee. This ensures that the rights of patients are protected even in urgent circumstances.
GCP guidelines emphasize that deferred consent is only allowed when pre-approved by the ethics committee as part of the protocol for emergency interventions.
"In emergencies, deferred consent is permitted only if outlined in the protocol and approved by the ethics committee, ensuring compliance with ethical standards." Objectives:
* Protect patient rights in emergency research.
* Ensure ethical approval for deferred consent.
NEW QUESTION # 60
Which statement does NOT represent a study monitor's responsibilities?
- A. Provide communication between the sponsor and the PI.
- B. Report serious adverse events to the IRB/IEC.
- C. Check the accuracy and completeness of case report forms with source documents.
- D. Verify that the PI has adequate qualifications and resources to conduct the study.
Answer: B
Explanation:
It is not the monitor's responsibility to report serious adverse events (SAEs) to the IRB/IEC. This responsibility typically falls on the PI or the sponsor. Monitors focus on data accuracy, protocol compliance, and communication between the site and the sponsor.
The answer follows GCP standards where the monitor's role is clearly defined, excluding SAE reporting to IRB/IEC.
"Monitors are responsible for verifying data accuracy and communicating with the sponsor but not for direct reporting of SAEs to the IRB/IEC." Objectives:
* Distinguish between the responsibilities of monitors and investigators
* Clarify SAE reporting protocols
NEW QUESTION # 61
A monitor identifies multiple deviations from a protocol-defined timeline for study procedures. The monitor is unable to identify proof of PI review and assessment of the deviations. The monitor discusses the deviations with the PI, who initiates a CAPA. What is the purpose of this CAPA?
- A. To establish a procedure for PI oversight of protocol deviations
- B. To determine if a protocol amendment is needed
- C. To determine if the deviations invalidate the data
- D. To escalate corrective actions to the regulatory authority
Answer: A
Explanation:
A Corrective and Preventive Action (CAPA) plan is implemented to address deviations and prevent them from recurring. In this context, the purpose of the CAPA is to establish a procedure for the Principal Investigator (PI) to ensure proper oversight of protocol deviations. This ensures that all future deviations are appropriately managed, reviewed, and documented according to GCP standards.
The answer is verified from GCP guidelines which emphasize that CAPA should focus on identifying root causes and establishing processes to prevent future deviations.
"A CAPA plan must address the root cause and implement systematic actions to prevent the recurrence of protocol deviations." Objectives:
* Ensuring PI oversight in protocol adherence
* Maintaining data integrity through systematic corrective actions
NEW QUESTION # 62
A representative from a regulatory authority shows up unannounced at a research site. After confirming their credentials, the representative requested to view the entire records, including identifiable information, from study XYZ that was closed out. Which of the following should the site personnel do next?
- A. Consult with the IRB/IEC first.
- B. Deny the request until the sponsor approves.
- C. Redact subject identification for privacy protection.
- D. Allow access to the entire records.
Answer: D
Explanation:
Regulatory authorities have the legal right to inspect clinical trial records, including identifiable information, even if the study has been closed out. After verifying the inspector's credentials, the site personnel must grant access to all requested documents to ensure compliance with regulations.
According to GCP guidelines, regulatory authorities have the right to access trial-related documents and data during inspections.
"Investigators must grant access to study records when requested by regulatory authorities as part of their inspection rights." Objectives:
* Ensure compliance with inspection requirements.
* Maintain transparency with regulatory authorities.
NEW QUESTION # 63
Who should vote during the IRB/IEC review and discussion process?
- A. All IRB/IEC members and non-member experts
- B. All members who were involved in the review and discussion and non-member experts
- C. All members who were involved in the review and discussion
- D. All IRB/IEC members
Answer: C
Explanation:
During the IRB/IEC review process, only members who actively participated in the review and discussion are eligible to vote. This ensures that votes are cast by those who are adequately informed about the study and can make an educated decision. Non-member experts may participate in discussions but do not have voting rights.
GCP guidelines state that voting rights in IRB/IEC meetings are limited to members who have thoroughly reviewed and discussed the study, maintaining unbiased and informed decision-making.
"Only IRB/IEC members who were involved in the review and discussion should participate in the voting process." Objectives:
* Ensure informed voting in ethical review processes.
* Maintain integrity and objectivity in IRB/IEC decisions.
NEW QUESTION # 64
When assessing the monitoring needs for a study, sponsors should:
- A. Permit PIs to select a monitor for their site as long as they are independent of the PI.
- B. Use central monitoring instead of conducting physical monitoring visits at sites.
- C. Ensure monitors have the scientific and/or clinical knowledge needed to monitor the trial adequately.
- D. Ensure monitoring visits are conducted at periodic intervals with a minimum of monthly monitoring visits.
Answer: C
Explanation:
Sponsors must ensure that monitors are adequately qualified, possessing the necessary scientific and clinical knowledge to effectively oversee the trial. This ensures that monitors can accurately assess protocol compliance, data integrity, and participant safety. The quality of monitoring directly impacts the credibility of the trial outcomes.
GCP guidelines specify that monitors must be adequately trained and knowledgeable about the trial protocol, investigational product (IP), and clinical research standards.
"The sponsor must ensure that monitors have appropriate qualifications and training to conduct effective trial monitoring." Objectives:
* Maintain data integrity through skilled monitoring.
* Ensure patient safety and protocol compliance.
NEW QUESTION # 65
A clinical trial is conducted to measure the effectiveness of music therapy to reduce anxiety in intensive care unit patients. Patients are randomly assigned to receive headphones with music of their choice or headphones with white noise. The group receiving the white noise headphones is considered which type of control group?
- A. Active control
- B. Alternate dose
- C. Placebo
- D. No treatment
Answer: C
Explanation:
In this trial, the white noise group acts as a placebo control. While they are receiving an intervention (white noise), it is not the active therapeutic intervention (music therapy) being tested. Placebo controls help in assessing the effect of the active intervention by comparing it to a neutral or non-therapeutic alternative.
GCP guidelines state that a placebo control is a neutral intervention used to compare the effects of an active treatment.
"A placebo group is one that receives a neutral intervention, used to measure the efficacy of the active intervention by comparison." Objectives:
* Differentiate between active and placebo control groups.
* Evaluate therapeutic efficacy objectively.
NEW QUESTION # 66
Confidentiality and privacy rules for protection of human subjects at research sites are determined by the:
- A. Applicable regulatory authorities
- B. Sponsor
- C. Applicable site SOPs
- D. PI
Answer: A
Explanation:
The confidentiality and privacy rules protecting human subjects in clinical research are established by applicable regulatory authorities, such as the FDA or EMA, and must be followed by all research sites. These regulations ensure that participants' personal data are handled securely and ethically.
GCP guidelines mandate compliance with local, national, and international regulations regarding data confidentiality and privacy.
"Confidentiality and privacy protections are determined by applicable regulatory authorities and must be adhered to by all study sites." Objectives:
* Protect participant privacy.
* Ensure compliance with data protection regulations.
NEW QUESTION # 67
......
Focus on ACRP-CP All-in-One Exam Guide For Quick Preparation: https://evedumps.testkingpass.com/ACRP-CP-testking-dumps.html